Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Tuesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Eagle Pharmaceuticals stock opened at $3.73 on Tuesday. The stock has a market capitalization of $48.45 million, a PE ratio of 3.16 and a beta of 0.53. The business has a 50 day simple moving average of $4.98 and a 200-day simple moving average of $4.84. Eagle Pharmaceuticals has a 12 month low of $3.21 and a 12 month high of $17.32.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in shares of Eagle Pharmaceuticals by 378.7% in the fourth quarter. BNP Paribas Financial Markets now owns 88,685 shares of the specialty pharmaceutical company’s stock valued at $464,000 after purchasing an additional 70,158 shares during the last quarter. Jump Financial LLC raised its stake in shares of Eagle Pharmaceuticals by 172.0% in the 4th quarter. Jump Financial LLC now owns 38,900 shares of the specialty pharmaceutical company’s stock valued at $203,000 after acquiring an additional 24,600 shares during the period. Trexquant Investment LP lifted its stake in Eagle Pharmaceuticals by 88.0% during the fourth quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock worth $660,000 after purchasing an additional 59,095 shares in the last quarter. Oxford Asset Management LLP purchased a new position in Eagle Pharmaceuticals during the 4th quarter valued at about $101,000. Finally, Aristides Capital LLC acquired a new position in shares of Eagle Pharmaceuticals in the fourth quarter valued at approximately $86,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.